Stockscreener 앱 받기
25.50
1.32%
-0.34
시장 영업 전:
25.35
-0.15
-0.59%
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
CAPR Stock In Spotlight As Investors Eye Next Week’s DMD Trial Data Showing Muscle And Cardiac Gains - Stocktwits
CAPR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Capricor (CAPR) Faces Challenges Amidst Stricter FDA Approval Pr - GuruFocus
Register: Aligning With the FDA on a Regulatory Pathway To Avoid Decision Day Surprises - BioSpace
(CAPR) Volatility Zones as Tactical Triggers - Stock Traders Daily
CAPR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Unpacking The 82% Potential Upside - DirectorsTalk Interviews
Capricor Therapeutics (CAPR) Schedule 13G: Suvretta reports 6.6% stake - Stock Titan
A Look At Capricor Therapeutics (CAPR) Valuation As Key Deramiocel Phase 3 Milestones Advance FDA Review - simplywall.st
Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference - Bitget
Duchenne trial to showcase Deramiocel Phase 3 data at 2026 MDA meeting - Stock Titan
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Asianet Newsable
Q3 2025 Capricor Therapeutics Inc Earnings Call Transcript - GuruFocus
Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Unveiling a 74% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
CAPR Stock Rallied Nearly 30% So Far This Week — Here’s The February FDA Catalyst Investors Are Betting On - Stocktwits
Capricor Therapeutics (NASDAQ:CAPR) Trading 12.2% HigherTime to Buy? - MarketBeat
GSA Capital Partners LLP Makes New $1.56 Million Investment in Capricor Therapeutics, Inc. $CAPR - MarketBeat
Highbridge discloses 2.3% Capricor Therapeutics (CAPR) stake via warrants - Stock Titan
What’s the profit margin of Capricor Therapeutics IncEarnings Growth Report & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Aug PostEarnings: Whats the profit margin of Capricor Therapeutics IncForecast Cut & Reliable Price Action Trade Plans - baoquankhu1.vn
Capricor Therapeutics, Inc. (CAPR) Stock Analysis: A 114% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Breakout Move: Whats the profit margin of Capricor Therapeutics Inc2025 Bull vs Bear & Weekly Momentum Stock Picks - baoquankhu1.vn
Why Capricor Therapeutics Inc. stock could see breakout soonEarnings Growth Summary & Long-Term Capital Growth Strategies - mfd.ru
How cyclical is Capricor Therapeutics Inc.’s revenue streamWeekly Trend Summary & Long-Term Capital Growth Strategies - mfd.ru
Following Sarepta Woes, Others Look To Unlock the Next Chapter in DMD Treatment - BioSpace
(CAPR) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Above 50-Day Moving AverageTime to Sell? - MarketBeat
Capricor Therapeutics Stock Becomes Talk Of Retail Town On DMD Study; Retail Sees New Hope After Sarepta Setback - MSN
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
A Look At Capricor Therapeutics (CAPR) Valuation After Its New Shelf Registration Filing - Sahm
Phase III wins propel Capricor, Belite and DBV higher in December - BioWorld MedTech
TANG CAPITAL MANAGEMENT LLC Acquires Significant Stake in Capric - GuruFocus
Capricor Therapeutics, Inc. (CAPR): Uncovering the 124.68% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Oppenheimer reiterates Outperform rating on Capricor stock, maintains $54 target - Investing.com Canada
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.7%Here's Why - MarketBeat
Does FDA’s No-New-Trial Stance on Deramiocel Shift the Bull Case for Capricor Therapeutics (CAPR)? - Sahm
Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Above 50 Day Moving AverageShould You Sell? - MarketBeat
(CAPR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
A Look At Capricor Therapeutics (CAPR) Valuation As FDA Advances Review Of Deramiocel BLA - Sahm
FDA Completes Inspection of Capricor Therapeutics Manufacturing Facility For Deramiocel Approval: Retail Sees ‘Unimaginable Potential’ - MSN
Tang Capital group reports 6.6% Capricor (NASDAQ: CAPR) ownership on Schedule 13G - Stock Titan
Highs Report: Whats the profit margin of Capricor Therapeutics IncBull Run & Weekly Stock Breakout Alerts - baoquankhu1.vn
Capricor Therapeutics, Inc. (CAPR): Investor Outlook On Promising 110% Upside Potential - DirectorsTalk Interviews
CAPR stock slides after FDA requests more data for genetic disorder therapy — what does retail think? - MSN
CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February - TradingView — Track All Markets
Does FDA’s HOPE-3 Data Request Clarify Deramiocel’s Regulatory Path For Capricor Therapeutics (CAPR)? - Sahm
Is FDA’s No-New-Trial Stance on Deramiocel Reshaping the Investment Case for Capricor Therapeutics (CAPR)? - Yahoo Finance
Is Capricor Therapeutics (CAPR) Still Attractive After A 72% One Year Share Price Jump - Yahoo Finance
Capricor Updates Deramiocel BLA Status After FDA Review of HOPE-3 Data - filmogaz.com
Capricor Therapeutics (CAPR) Valuation After FDA Requests HOPE-3 Data For Deramiocel Regulatory Review - Yahoo Finance
Capricor (CAPR) Plans February FDA Data Submission After 2% Stock Drop - Intellectia AI
CAPR Stock Slides After FDA Requests More Data For Genetic Disorder Therapy — What Does Retail Think? - Stocktwits
FDA Requests Capricor To Submit HOPE-3 Clinical Study Report For Deramiocel BLA Review - RTTNews
Capricor Therapeutics Provides Regulatory Updates Regarding Its Biologics License Application for Deramiocel - marketscreener.com
Capricor Therapeutics (CAPR) Moves Forward with Regulatory Update on Cell Therapy - GuruFocus
Capricor Therapeutics Inc. Provides Regulatory Update on Deramiocel BLA Submission Following FDA Request for HOPE-3 Clinical Study Report - Quiver Quantitative
FDA asks for full HOPE-3 data on DMD cell therapy, no new trials - Stock Titan
Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50 Day Moving AverageHere's Why - MarketBeat
0.11%
6.00%
자본화:
|
볼륨(24시간):